Related Experiment Videos
Proliferative activity in human glioblastomas assessed by various techniques
1Department of Laboratory Medicine, Faculty of Medicine, Norwegian University of Science and Technology. sverre.torp@medisin.ntnu.no
APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|February 16, 2002
Summary
Assessing tumor proliferation is key for glioblastoma diagnosis. While Ki67 antibodies and other markers vary, mitotic counting remains reliable for astrocytic tumors, especially with histopathology.
Area of Science:
- Oncology
- Pathology
- Biomarkers
Background:
- Proliferative activity is crucial for glioblastoma diagnosis and prognosis.
- Accurate assessment of tumor cell proliferation aids in treatment planning and outcome prediction.
Purpose of the Study:
- To compare the efficacy of commonly used proliferation markers in human glioblastoma.
- To evaluate Ki67 antibodies, PCNA, and bcl-2 for assessing tumor proliferation.
- To determine the reliability of S-phase fraction and mitotic activity measurements.
Main Methods:
- Immunohistochemical staining of 12 glioblastoma cases using four Ki67 antibodies, anti-PCNA, and anti-bcl-2.
- Determination of S-phase fraction via flow cytometry.
- Assessment of mitotic activity through direct counting.
Main Results:
- Ki67 antibodies showed variability in proliferation indices (PI) within and between tumors.
- Correlations between Ki67 and other markers (PCNA, bcl-2) were generally poor.
- Flow cytometry provided reliable S-phase fraction values, detecting two aneuploid tumors.
- Mitotic activity was consistently high across samples.
Conclusions:
- Mitotic counting is a reliable method for assessing proliferative activity in astrocytic tumors.
- Ki67 antibodies serve as valuable alternatives, particularly for stereotactic biopsies.
- Proliferation markers should complement established histopathological criteria for malignancy assessment.